J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 M e d i c a l u s e s
T o g g l e M e d i c a l u s e s s u b s e c t i o n
1 . 1 I n t r a v e s i c a l u s e
2 S i d e e f f e c t s
3 H i s t o r y
4 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
T h i o t e p a
1 6 l a n g u a g e s
● ا ل ع ر ب ي ة ● ت ۆ ر ک ج ه ● C y m r a e g ● D e u t s c h ● E s p a ñ o l ● ف ا ر س ی ● I t a l i a n o ● 日 本 語 ● ଓ ଡ ଼ ି ଆ ● P o l s k i ● R o m â n ă ● С р п с к и / s r p s k i ● S r p s k o h r v a t s k i / с р п с к о х р в а т с к и ● S u o m i ● T i ế n g V i ệ t ● 中 文
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
I n o t h e r p r o j e c t s
● W i k i m e d i a C o m m o n s
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Tepadina
Monograph
a682821
Intravenous , intracavitary, intravesical
UK POM (Prescription only)
US WARNING [1] [4]
EU [5]
Liver (CYP2B6 , CYP3A )
1.5–4.1 hours
Kidney
1,1′ ,1′ ′ -Phosphorothioyltriaziridine
100.000.124
Chemical and physical data
C 6 H 12 N 3 P S
−1
InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2 Y
Key:FOCVUCIESVLUNU-UHFFFAOYSA-N Y
Thiotepa (INN [6] Tepadina , is a medication used to treat cancer .[4] [5] [7]
Thiotepa is an organophosphorus compound with the formula (C 2 H 4 N )3 [8] analog of N N ′ N ″TEPA ), which contains tetrahedral phosphorus and is structurally akin to phosphate . It is manufactured by heating aziridine with thiophosphoryl chloride .[citation needed
Medical uses [ edit ]
Thiotepa is indicated for use in combination with other chemotherapy agents to treat cancer.[4] [5] [7] total body irradiation (TBI), as a conditioning treatment prior to allogeneic or autologous hematopoietic progenitor cell transplantation (HPCT) in hematological diseases in adults and children.[5] [7] [7] [5] [7]
Thiotepa is used in the palliation of many neoplastic diseases . The best results are found in the treatment of adenocarcinoma of the breast , adenocarcinoma of the ovary , papillary thyroid cancer and bladder cancer . Thiotepa is used to control intracavitary effusions caused by serosal neoplastic deposits.[7]
Intravesical use [ edit ]
Thiotepa is used as intravesical chemotherapy in bladder cancer.[9]
It may be used prophylactically to prevent seeding of tumor cells at cystoscopic biopsy; as an adjunctive agent at the time of biopsy; or as a therapeutic agent to prevent recurrence after cystoscopic resection of bladder tumor (transurethral resection of bladder tumor , TURBT).[medical citation needed Efficacy in tumor control may reach 55%.[medical citation needed The main toxicity of this therapy is bone marrow suppression due to systemic absorption of the drug.[medical citation needed
Side effects [ edit ]
The main side effect of thiotepa is bone marrow suppression resulting in leukopenia , thrombocytopenia and anemia .[10] [medical citation needed
History [ edit ]
Thiotepa was developed by the American Cyanamid company in the early 1950s and reported to media outlets in 1953.[11] Food and Drug Administration (FDA) as a drug therapy for several solid cancers.[12]
In January 2007, the European Medicines Agency (EMA) designated thiotepa as an orphan drug . In April 2007, the United States FDA designated thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation .[13]
In 2024 The (FDA) approved the New Drug Application (NDA) for Tepylute, a ready-to-dilute formulation of thiotepa to treat breast and ovarian cancer .[14] [15]
References [ edit ]
^ "Cancer therapies" . Health Canada . Retrieved 13 April 2024 .
^ a b c "Tepadina- thiotepa injection, powder, for solution" . DailyMed . Archived from the original on 12 August 2021. Retrieved 11 August 2021 .
^ a b c d e "Tepadina EPAR" . European Medicines Agency (EMA)Archived from the original on 6 March 2021. Retrieved 30 April 2021 .
^ "International Non-Proprietary Names for Pharmaceutical Preparations. Recommended International Non-Proprietary Names (Rec. I.N.N.): List 4" (PDF) . World Health Organization. March 1962. p. 111. Archived from the original (PDF) on 18 May 2016. Retrieved 27 November 2016 .
^ a b c d e f "Urgent, Thiotepa update" (PDF) . U.S. Food and Drug Administration (FDA). 5 April 2011. Archived (PDF) from the original on 9 November 2011. Retrieved 25 November 2011 .
^ Maanen MJ, Smeets CJ, Beijnen JH (August 2000). "Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA)". Cancer Treatment Reviews . 26 4 ): 257–68. doi :10.1053/ctrv.2000.0170 . PMID 10913381 .
^ Droller M (2004). Urothelial Tumors ISBN 978-1-55009-173-1 Archived from the original on 11 January 2023. Retrieved 16 September 2017 .
^ Agnelli G, de Cunto M, Gresele P, del Favero A (June 1982). "Early onset life-threatening myelosuppression after low dose of intravesical thiotepa" . Postgraduate Medical Journal . 58 doi :10.1136/pgmj.58.680.380 . PMC 2426344 PMID 6812036 .
^ Sykes MP, Karnofsky DA, Philips FS, Burchenal JH (1953). "Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity" . Cancer . 6 1 ): 142–148. doi :10.1002/1097-0142(195301)6:1<142::AID-CNCR2820060114>3.0.CO;2-W
^ Kim KM, Roh JK, Wee H, Kim C (2016). Cancer Drug Discovery: Science and History . Springer. p. 82. ISBN 978-94-024-0844-7
^ "EMA Grants Adienne Marketing Rights for Tepadina" . Drug Discovery & Development. 19 March 2010. Retrieved 25 November 2011 .
^ "Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer" .
^ "FDA Approves Tepylute in Breast and Ovarian Cancer" . Targeted Oncology . 28 June 2024. Retrieved 29 June 2024 .
Vinflunine §
Vinorelbine # )
Block microtubule disassembly
Docetaxel #
Larotaxel
Ortataxel †
Paclitaxel #
Tesetaxel )
Epothilones Ixabepilone )
Raltitrexed )
Carmofur
Doxifluridine
Floxuridine
Fluorouracil #
Tegafur (+gimeracil/oteracil ))
Etirinotecan pegol †
Exatecan
Gimatecan
Irinotecan #
Lurtotecan ‡
Rubitecan ‡
Silatecan §
Topotecan )
Teniposide )
Amrubicin †
Daunorubicin # (+cytarabine )
Doxorubicin #
Epirubicin
Idarubicin
Pirarubicin
Valrubicin
Zorubicin )
Anthracenediones Losoxantrone
Mitoxantrone
Pixantrone )
Amsacrine
Bisantrene
Crisnatol
Menogaril §
Trofosfamide )
Chlorambucil #
Melphalan (Melphalan flufenamide )
Prednimustine
Uramustine
Cisplatin #
Dicycloplatin
Nedaplatin
Oxaliplatin #
Satraplatin
Hydrazines Procarbazine # )
Etoglucid
Mitobronitol
Pipobroman
Triazenes Dacarbazine #
Mitozolomide §
Temozolomide )
Bleomycin #
Mitomycins
Plicamycin )
Efaproxiral
Methyl aminolevulinate
Padeliporfin
Porphyrin derivatives Porfimer sodium
Talaporfin
Temoporfin
Verteporfin )
Palbociclib
Ribociclib
Seliciclib † )
PrI
PhI Anagrelide )
IMPDI Tiazofurin § )
LI Masoprocol )
PARP inhibitor Fuzuloparib
Niraparib +abiraterone acetate
Olaparib
Rucaparib )
HDAC Belinostat
Entinostat
Panobinostat
Romidepsin
Vorinostat )
PIKI (Pi3K)Alpelisib
Copanlisib
Duvelisib
Idelalisib
Umbralisib ‡ )
Retinoid X receptor Bexarotene )
Sex steroid Testolactone )
Aflibercept
Arsenic trioxide
Asparagine depleters Asparaginase # /Pegaspargase )
Axicabtagene ciloleucel
Belzutifan
Bexarotene
Brexucabtagene autoleucel
Celecoxib
Ciltacabtagene autoleucel
Demecolcine
Denileukin diftitox
Eflornithine
Elesclomol §
Elsamitrucin
Enasidenib
Epacadostat
Eribulin
Estramustine
Glasdegib
Idecabtagene vicleucel
Imetelstat
Ivosidenib
Lifileucel
Lonidamine
Lucanthone
Lurbinectedin
Mitoguazone
Mitotane
Navitoclax
Oblimersen †
Omacetaxine mepesuccinate
Plitidepsin
Retinoids Alitretinoin
Tretinoin # )
Selinexor
Sitimagene ceradenovec
Sotorasib
Tagraxofusp
Talimogene laherparepvec
Tazemetostat
Tebentafusp
Tiazofurine
Tigilanol tiglate
Tisagenlecleucel
Trabectedin
Veliparib
Venetoclax
Verdinexor
Vosaroxin
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Thiotepa&oldid=1231942005 " C a t e g o r i e s : ● A l k y l a t i n g a n t i n e o p l a s t i c a g e n t s ● A z i r i d i n e s ● C a n c e r t r e a t m e n t s ● I A R C G r o u p 1 c a r c i n o g e n s ● O r g a n o p h o s p h o r i c a m i d e s ● O r p h a n d r u g s ● T h i o p h o s p h o r y l c o m p o u n d s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● U s e d m y d a t e s f r o m A p r i l 2 0 2 4 ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● A r t i c l e s w i t h c h a n g e d D r u g B a n k i d e n t i f i e r ● E C H A I n f o C a r d I D f r o m W i k i d a t a ● D r u g b o x e s w h i c h c o n t a i n c h a n g e s t o v e r i f i e d f i e l d s ● D r u g b o x e s w h i c h c o n t a i n c h a n g e s t o w a t c h e d f i e l d s ● A l l a r t i c l e s w i t h u n s o u r c e d s t a t e m e n t s ● A r t i c l e s w i t h u n s o u r c e d s t a t e m e n t s f r o m M a y 2 0 2 1
● T h i s p a g e w a s l a s t e d i t e d o n 1 J u l y 2 0 2 4 , a t 0 3 : 0 3 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
Y
N
